Does Arcus Biosciences (RCUS) Pay a Dividend? (2026)

No. Arcus Biosciences has no dividend on record, so the yield is 0% and holding RCUS produces no income. Arcus Biosciences is not consistently profitable yet (net loss of $91 million, or $0.72 per share, in the second quarter of 2026, and $219 million, or $1.74 per share, for the first half on 125.7 million weighted-average shares. The trailing twelve-month loss is ~$460 million, or ~$3.86 per share. Fiscal 2025 produced a $353 million loss and fiscal 2024 a $283 million loss. Accumulated deficit stands at $1.704 billion. No P/E ratio exists and no income tax was recorded, given forecast full-year net operating losses.), and companies do not usually start returning cash before earnings are durable. Every dollar of return from RCUS has to come from the share price. Verify the current policy on RCUS's investor relations page, since a board can start a dividend at any time.

Arcus Biosciences is not consistently profitable yet (net loss of $91 million, or $0.72 per share, in the second quarter of 2026, and $219 million, or $1.74 per share, for the first half on 125.7 million weighted-average shares. The trailing twelve-month loss is ~$460 million, or ~$3.86 per share. Fiscal 2025 produced a $353 million loss and fiscal 2024 a $283 million loss. Accumulated deficit stands at $1.704 billion. No P/E ratio exists and no income tax was recorded, given forecast full-year net operating losses.), and companies do not usually start returning cash before earnings are durable. Its free cash flow position (cash, cash equivalents and marketable securities of $775 million at June 30, 2026, made up of $150 million cash, $552 million current marketable securities and $73 million long term, down from $1.01 billion at December 31, 2025. Operating cash use was $257 million in the first half. Total assets were $924 million, current liabilities $198 million, long-term debt $101 million under the Hercules facility maturing September 2030, and stockholders' equity $464 million. Guidance is ~$600 million of cash at year-end 2026 and runway into at least the second half of 2028.) is the constraint that matters most here: a dividend is a standing commitment, and starting one before cash generation is reliable would mean funding it from the balance sheet. Paying nothing is a deliberate choice, not a failure. A growth company that can reinvest at high returns creates more value per dollar retained than it would by handing that dollar to shareholders.

Nobody can say, and we will not guess. What usually has to happen first is a stretch of durable profitability and positive free cash flow, with enough left over after reinvestment that the company runs out of better uses for the money. Watch for those in the quarterly results rather than for an announcement. Companies also often start with buybacks before a dividend, because a buyback carries no ongoing commitment.

0%. There is no dividend, so there is no yield. This matters for planning: if you are building an income portfolio, RCUS contributes nothing to the income side and its entire contribution is price return. It also means the position generates no taxable income while you hold it.

The usual approach is to pair a non-payer like RCUS with holdings that do pay: dividend stocks, dividend ETFs, or bond funds, sized so the income side of the portfolio meets your needs while the growth side stays intact. Some investors sell covered calls on positions they hold, though that caps the upside that is the whole reason to own a growth name. See our guides to the best dividend stocks and best dividend ETFs. Walnut is not an investment adviser.

Not while you hold it. With no dividend there is no income to report, so nothing is taxable until you sell. At that point you owe capital-gains tax on the gain, at long-term rates if you held for more than a year and at ordinary-income rates if you did not. That deferral is a genuine, if minor, advantage of non-payers in a taxable account. This is not tax advice.

It is the wrong tool for that job, which is not the same as a bad company. If you need cash from your portfolio, a stock paying nothing forces you to sell shares to generate it, which means selling into whatever price the market happens to offer. Investors who want RCUS's growth exposure and also want income typically hold both, rather than expecting one holding to do both jobs.

No. Arcus Biosciences pays no dividend and has never declared one. The company loses money at every line, used $257 million of cash in operations during the first half of 2026 alone, and is funding one Phase 3 study plus a second registrational trial due to start by year end. A capital return of any kind would sit badly against that position, and the Hercules loan agreement, secured by substantially all of the company's assets and carrying a minimum cash covenant that begins in July 2027, adds a further constraint. Anyone holding RCUS is exposed entirely to share price movement driven by clinical results, partnership terms and financing decisions. Income allocations in a portfolio are typically met elsewhere, from established pharmaceutical companies or healthcare funds that distribute.